Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen's Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.
CEO Joe Turgeon said in an interview that the company aims to focus more on developing drugs for larger, broader and more lucrative oncology markets.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.